ANXA8 and cancer: ANXA8 positive rate and high positive rate in the malignant tumor group (90.12% and 72.84%, respectively) were significantly higher than those in the borderline tumor group (47.06% and 29.41%, respectively), benign tumor group (38.46% and 23.08%, respectively), and normal ovary group (18.18% and 9.09%, respectively; P < 0.05).